Datavault AI (NASDAQ: DVLT) announced an expansion of its definitive licensing agreement with DataMeds AI Inc., extending its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The amended agreement, announced July 30, 2026, is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments. This leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the expanded agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion is significant as it moves blockchain-based health data management from a niche pharmaceutical application into broader commercial healthcare, where patients could gain greater control over their medical data and potentially monetize it. The global health and wellness market is rapidly growing, and patient-controlled data models could disrupt traditional healthcare data silos. Datavault AI’s technology, which includes AI-driven data experiences and asset monetization in the Web 3.0 environment, is now positioned to address these opportunities. The company’s cloud-based platform provides solutions across its Acoustic Sciences and Data Sciences divisions, with the latter focusing on Web 3.0 and high-performance computing for data perception, valuation and secure monetization.
For the healthcare industry, this could mean more efficient data sharing, reduced administrative burdens, and new revenue streams for patients and providers. The tokenization of real-world assets, such as health data, could also enable new financial instruments. Datavault AI’s platform serves multiple industries including biotech, fintech, and healthcare, and the expansion into commercial healthcare broadens its addressable market. The company’s technology suite includes AI- and machine-learning-based automation, third-party integration, and detailed analytics, which could be applied to remote patient monitoring and population health management.
Investors and industry observers should note that the amended agreement replaces preferred shares with common shares for tax optimization, which may affect the company’s capital structure. Datavault AI is headquartered in Philadelphia, PA, and its technology is used in sectors such as sports & entertainment, events, and energy. The full press release is available at https://ibn.fm/vBAxH. Forward-looking statements in the announcement involve risks and uncertainties, as detailed in the company’s SEC filings. More information about Datavault AI can be found at https://dvlt.ai.
